MedPath

Haloperidol vs. Valproate in Agitation

Phase 3
Completed
Conditions
Psychomotor Agitation
Interventions
Registration Number
NCT01750541
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

The aim of this study is to compare the efficacy of haloperidol and valproate in management of people with agitation in emergency department

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Clinical diagnosis of psychomotor agitation
  • aged 18 to 65 years
Exclusion Criteria
  • Pregnant patients
  • Severe liver disease
  • History of drug (haloperidol/valproate) allergy
  • Readily amendable causes for the agitation (hypoxemia or hypoglycemia)
  • Hypotension (systolic blood pressure (SBP) ≤ 90 mm Hg)
  • Known history of liver disease or uncontrolled diabetes
  • Noticeable or suspected head trauma
  • Previous history of neuroleptic malignant syndrome
  • Receiving psychotropic medication, neuroleptic agents or cholinesterase inhibitors at the time of enrollment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HaloperidolHaloperidolHaloperidol 5mg intramuscular injection
ValproateValproateValproate single Infusion; 400 mg (weigh\<60 kg), 500 mg (weight\>60 Kg)
Primary Outcome Measures
NameTimeMethod
Reduction in Agitated Behavior Scale (ABS) scorewithin the first 30 minutes of treatment onset

Patients were rated before medication administration and within 30 minutes afterwards according to Agitated Behavior Scale (ABS) score. Any statistically significant change in ABS score consider as positive effect of either intervention.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Emergency Medicine, Imam Hossein Hospital

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath